METHOD OF SPONTANEOUS REPORTS AS AN INSTRUMENT CONTROLING WIDELY USED INTERCHANGEABLE DRUGS

Download full text PDF
Issue: 
9
Year: 
2016

E. Pasternak (1); K. Zatolochina (1), Candidate of Medical Sciences; Professor R. Alyautdin (1), MD; Yu. Olefir (1), MD; B. Romanov (1), MD; I. Asetskaya (2), Candidate of Medical Sciences 1 -Scientific Centre for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation, Moscow 2 - Informational-Methodological Center for the Expertise, Accounting and Analysis of Medical Products Circulation under Roszdravnadzor, Moscow

Method of spontaneous reports was used to identify adverse reactions associated with the replacement of the drugs with the same international nonproprietary name. The analysis of 7224 spontaneous reports in Russian data base for the period from 1 January 2015 to 30 June 2015 was done. Information about adverse reactions that occur when there was the replacement of drugs was detected in 1.9% of cases. The obtained results allowed to detect the following groups of drugs for which it was revealed the largest number of spontaneous reports of adverse reactions associated with the replacement of drugs: anti-epileptic drugs (45.9%), drugs with a narrow therapeutic index (39.2%), biologic drugs (3.7%), pancreatin (4.4%), ipratropium bromide+fenoterol (2.2%), drugs used in pediatrics (34.1%). Data that were obtained via method of spontaneous reports can be used for the primary and repeated evaluation interchangeability of medicinal drugs.

Keywords: 
pharmacology
interchangeability
bioequivalence
therapeutic equivalence
generics
spontaneous reports
adverse drug reaction
method of spontaneous reports



It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. The Use of Generic Anti-Epileptics Drugs in Patients with Epilepsy. 2014. 1. Available at: http://www.epilepsysociety.org.uk/sites/default/files/The%20Use%20of%20Generic%20Anti%20Epileptics%20Drugs%20in%20Patients%20with%20Epilepsy.pdf (accessed 11 July 2016).
  2. Crawford P., Feely M., Guberman A. et al. Are there potential problems with generic substitution of antiepileptic drug? // Seizure. – 2006; 15: 165–76.
  3. Rukovodstvo po ekspertize lekarstvennyh sredstv. T. IV / M.: Poligraf Pljus, 2014; 172 s.
  4. Federal'nyj zakon ot 22.12.2014 №429-FZ «O vnesenii izmenenij v Federal'nyj zakon “Ob obraschenii lekarstvennyh sredstv”».
  5. Romanov B.K., Bunjatjan N.D., Olefir Ju.V. i dr. Rekomendatsii po porjad ku opredelenija vzaimozamenjaemosti lekarstvennyh preparatov // Vedomosti Nauchnogo tsentra ekspertizy sredstv meditsinskogo primenenija. – 2015; 2: 3–8.
  6. Meir B. Generic products of Antiepileptic Drugs (AEDs): Is it an issue? // Epilepsia. – 2007; 48: 1825–32.
  7. Zatolochina K.E., Aljautdin R.N., Zhuravleva E.O. i dr. O vzaimozame njaemosti ingibitorov kal'tsinevrina // Bezopasnost' i risk farmakotera-pii. – 2016; 2: 5–10.
  8. Updated Questions and Answers for Healthcare Professionals and the 8. Public: Use an Approved Pancreatic Enzyme Product (PEP). 17 May 2012. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm204745.htm (accessed 11 July 2016.)
  9. Simonova O.I., Roslavtseva E.A. Osobennosti zamestitel'noj fer mentoterapii pri mukovistsidoze u detej: preimuschestva vysokotehnolo-gichnyh fermentnyh preparatov. 2011. Available at: http://cyberleninka.ru/article/n/osobennosti-zamestitelnoy-fermentoterapii-pri-mukovistsidoze-u-detey-preimuschestva-vysokotehnologichnyh-fermentnyh-preparatov (accessed 11 July 2016).
  10. Laszlo Tothfalusi, Laszlo Endrenyi, Shein-Chung Chow Eur. Statistical and regulatory considerations in assessments of interchangeability of biological drug products // J. Health Econ. – 2014; 15 (Suppl. 1): 5–11.
  11. Soldatov A.A., Avdeeva Zh.I., Olefir Ju.V. i dr. Bezopasnost' biolo gicheskih preparatov. Soobschenie 2. Problemy bezopasnosti biopodobnyh preparatov // Biopreparaty. Profilaktika, diagnostika, lechenie. – 2016; 16 (2): 78–89.
  12. Kutehova G.V., Lepahin V.K., Romanov B.K. Vyjavlenie naznachenija lekarstvennyh sredstv s narushenijami predpisanij instruktsii (off-label) v pediatricheskoj praktike // Vedomosti Nauchnogo tsentra ekspertizy sredstv meditsinskogo primenenija. – 2012; 3: 23–7.
  13. Zavidova S.S., Namazova-Baranova L.S., Topoljanskaja S.V. Klinicheskie issledovanija lekarstvennyh preparatov v pediatrii: problemy i dostizhe-nija // Pediatricheskaja farmakologija. – 2010; 1 (7): 6–14.
  14. Romanov B.K., Toropova I.I., Kolesnikova E.Ju. Nepravil'noe prime nenie lekarstvennyh sredstv // Bezopasnost' i risk farmakoterapii. – 2014; 2 (3): 28–30.
  15. Romanov B.K., Glagolev S.V., Polivanov V.A. i dr. Monitoring bezopas nosti lekarstvennyh sredstv // Bezopasnost' i risk farmakoterapii. – 2014; 3 (4): 11–4